Advertisement

Topics

Latest "Placebo Hepatitis Virus Infection" News Stories

19:49 EDT 5th May 2016 | BioPortfolio

Here are the most relevant search results for "Placebo Hepatitis Virus Infection" found in our extensive news archives from over 250 global news sources.

More Information about Placebo Hepatitis Virus Infection on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Placebo Hepatitis Virus Infection for you to read. Along with our medical data and news we also list Placebo Hepatitis Virus Infection Clinical Trials, which are updated daily. BioPortfolio also has a large database of Placebo Hepatitis Virus Infection Companies for you to search.

Showing "Placebo Hepatitis Virus Infection" News Articles 1–25 of 9,300+

Extremely Relevant

Hepatitis C virus uses Netrin-1 to hijack host cells

Hepatitis C virus (HCV) is a small, enveloped virus comprising an RNA genome encased in a protein capsid and surrounded by a lipid bilayer containing two glycoproteins. Acute infection can cause hepatitis but the virus usually persists as a chronic infection of the liver where it can cause inflammation and, eventually, hepatocellular carcinoma. How HCV subverts hepatocytes to turn them into virus-...


Screening and Prevention of Hepatitis B Virus Reactivation During Chemotherapy

The incidence of both hepatitis B virus infection and cancer is common. The use of immunosuppressive therapy in patients with hepatitis B virus can result in reactivation of hepatitis B virus, which can, in turn, lead to significant morbidity and mortality.

Counterattack of the hepatitis B virus

The hepatitis B virus (HBV), which is up to 100 times more infectious than HIV, is primarily transmitted through blood or other bodily fluids. HBV infects liver cells and chronic infection can lead to serious health problems such as cirrhosis or liver cancer. According to the World Health organization, chronic hepatitis B affects nearly 240 million people worldwide, killing almost 800,000 people a...


Baraclude safely reduces HBV DNA among children, adolescents

In a randomized phase 3 study, children and adolescents with chronic hepatitis B virus infection treated with Baraclude showed reduced infection compared with children treated with placebo, according to published findings. Researchers randomly assigned 180 treatment-naive children and adolescents to a regimen of Baraclude (entecavir, Bristol-Myers Squibb; n = 120) or placebo (n = 60) for a duratio...

Hepatitis C Linked to Increased Risk of Parkinson’s

People infected with the hepatitis C virus may have an increased risk of developing Parkinson’s disease, according to a new study out of Taiwan.  Hepatitis C is a liver infection caused by a virus. Between 130 million and 150 million people worldwide have chronic hepatitis C infection, according to the World Health Organization.

CDC Urges Dialysis Providers to Improve Infection Control to Stop Hepatitis C Virus Transmission

The Centers for Disease Control and Prevention (CDC) has received an increased number of reports of newly acquired hepatitis C virus (HCV) infection among patients undergoing hemodialysis. Infection control lapses in dialysis care could expose patients to HCV. Any case of new HCV infection in a patient undergoing hemodialysis should prompt

Risk of hepatitis B reactivation low in patients with RA treated with rituximab

Patients with rheumatoid arthritis and resolved hepatitis B virus infection who underwent treatment with rituximab did not experience reactivation of the infection, according to results of a multicenter Italian study.Researchers retrospectively studied data from 306 consecutive patients with rheumatoid arthritis (RA) who received treatment with rituximab (Rituxan, Genentech/Biogen Idec). Complete ...

Eiger licenses lambda to investigate potential therapy for hepatitis delta

Eiger BioPharmaceuticals Inc. announced it licensed pegylated interferon lambda-1a to Bristol-Myers Squibb to investigate the efficacy and safety of the drug as a therapeutic option for the treatment of hepatitis delta virus infection.Eiger plans to evaluate lambda, a type 3 interferon, as a potential monotherapy and combination regimen for individuals with chronic hepatitis delta virus (HDV) infe...

[Comment] Apportioning blame in the North American hepatitis C virus epidemic

A novel investigation into the North American spread of hepatitis C virus permits blame shifting, which the authors Jeffrey Joy and colleagues hope will increase the number of baby boomers who undergo testing.1 The medical community can now take its share of the responsibility for hepatitis C virus infection in its conversations with the 1945–65 birth cohort. Joy and colleagues offer evidence th...

Head and Neck Cancers May Be Linked to Hepatitis C

WEDNESDAY, April 13, 2016 -- Hepatitis C may increase the risk for certain types of head and neck cancers, researchers say. Hepatitis C is a serious liver infection caused by a virus. It's the most common bloodborne infection in the United States,...

MMWR: Sexual Transmission of Hepatitis C Virus Among HIV-Infected Men Who Have Sex with Men --- New York City, 2005--2010

In the United States, an estimated 3.2 million persons are living with hepatitis C virus (HCV) infection. HCV transmission occurs primarily through percutaneous exposure to blood, and persons who inject drugs are at greatest risk for infection. The role of sexual transmission of HCV has not been well defined. However, reports over the past decade, mainly from Europe, have implicated sexual tra...

Risk of liver cancer from hepatitis B persists even after clearing the virus

(Wiley) Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection was not associated with reduced rates of liver cancer.

Chronic kidney disease: Treatment of hepatitis C virus infection in patients with CKD

Treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease (CKD) can be challenging. Now, data from the phase III C-SURFER study show that grazoprevir and elbasvir — a new all-oral combination therapy for HCV — is safe and effective in patients with stage 4–5 CKD.

FDA Approves Expanded Use Of Roche Hepatitis C Virus RNA Test

Roche announced recently that it has received approval from the U.S. Food and Drug Administration (FDA) for its hepatitis C virus (HCV) quantitative RNA test to be used as an aid in the diagnosis of HCV infection for certain patient populations.

Targeted Hepatitis B Virus Screening Effective in Addressing Infection, Liver Disease Risk

A community-based hepatitis B virus screening effort led by UC Davis researchers found that targeted outreach to Asian American populations can identify groups at high risk for infection and direct them to appropriate follow-up care to help prevent the onset of liver diseases, including cancer. Published online today in Public Health Reports, the

Natural Immunity May Lead Fight Against Hepatitis C Virus, Liver Disease

University of Adelaide researchers have uncovered the role played by a family of genes, which can suppress hepatitis C virus (HCV) infection within the liver. The findings, published in the Journal of Biological Chemistry, shed light on the activity of these genes and how they produce a natural immune response to the virus. HCV is a major health

Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor

Chronic hepatitis B virus infection is a leading cause of cirrhosis and liver cancer. Hepatitis B virus encodes the regulatory HBx protein whose primary role is to promote transcription of the viral genome, which persists as an extrachromosomal DNA circle in infected cells. HBx accomplishes this task by an unusual mechanism, enhancing transcription only from extrachromosomal DNA templates. Here we...

Hepatitis C Tied to Increase Risk of Parkinson's

The hepatitis C virus may be associated with an increased risk of developing Parkinson's disease, according to a study published in the December 23, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology. Parkinson's disease is considered the second most common degenerative brain disorder after Alzheimer's disease. Hepatitis C is a liver infection caused by a vi...

Antiviral Therapies Give Hepatitis C Patients Similar Life Expectancy as General Population

The survival rate of patients with hepatitis C virus-related cirrhosis who respond well to antiviral therapies equals that of the general population, say investigators in the Journal of Hepatology. Long-term development of cirrhosis and liver disorders, such as decompensation or hepatocellular carcinoma, after infection with hepatitis C virus

Zepatier Approved for Chronic Hepatitis C

FRIDAY, Jan. 29, 2016 -- Zepatier (a combination of elbasavir and grazoprevir) has been approved by the U.S. Food and Drug Administration to treat chronic infection with the hepatitis C virus, genotypes 1 and 4. Hepatitis C causes liver...

NVR 3-778 safely reduces HBV DNA in chronic HBV patients

BARCELONA — In an ongoing phase 1b clinical trial, NVR 3-778, a hepatitis B virus core inhibitor, safely reduced HBV DNA levels in patients with chronic hepatitis B virus infection, according to a Late Breaker presentation at International Liver Congress.“There is no formal name for this medication, but it is a first-in-class inhibitor,” Man-Fung Yuen, MBBS, MD, PhD, chair and professor of g...

Medical News Today: Liver cancer risk lingers after hepatitis B virus cleared

A new study finds that the risk of developing liver cancer from infection with hepatitis B persists even after patients have apparently been cleared of the virus.

Hepatitis C Positive Antibody Test Leads to Molecular Assay

Conventional laboratory and medical practice for Hepatitis C virus infection involves referring a patient for a second office visit and blood draw...

Harvoni effective for patients with HIV, acute HCV

BOSTON — Harvoni was safe and effective for the treatment of patients with HIV with acute hepatitis C virus infection, according to a Late Breaker presented at CROI 2016.“We are all familiar with this fixed dosed combination for the treatment of hepatitis C. However, there is currently no approved DAA therapy for patients with acute hepatitis C virus infection, including those with HIV coinfec...

A New Era of Therapy for Hepatitis C Virus Infection

IFN-free regimens with direct-acting antivirals have quickly become the mainstay of treatment for HCV infection. Read more about them here. Current Opinion in Infectious Diseases


Quick Search
Advertisement
 

News Quicklinks